{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:35:53Z","timestamp":1785803753833,"version":"3.56.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bonr.2022.101617","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T02:40:38Z","timestamp":1661827238000},"page":"101617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Impact of discontinuing 5\u00a0years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series"],"prefix":"10.1016","volume":"17","author":[{"given":"Cheryl","family":"Rockman-Greenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Mhanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bonr.2022.101617_bb0005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","article-title":"Hypophosphatasia: clinical manifestation and burden of disease in adult patients","volume":"14","author":"Conti","year":"2017","journal-title":"Clin. Cases Miner. Bone Metab."},{"issue":"20","key":"10.1016\/j.bonr.2022.101617_bb0010","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1073\/pnas.85.20.7666","article-title":"A missense mutation in the human liver\/bone\/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia","volume":"85","author":"Weiss","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bonr.2022.101617_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview for 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"issue":"Suppl. 3","key":"10.1016\/j.bonr.2022.101617_bb0020","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s10545-009-9012-y","article-title":"Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5\u2019-phosphate availability","volume":"33","author":"Balasubramaniam","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bonr.2022.101617_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-2-40","article-title":"Hypophosphatasia","volume":"2","author":"Mornet","year":"2007","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.bonr.2022.101617_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115695","article-title":"Characterization of physical, functional, and cognitive performance in 15 adults with hypophosphatasia","volume":"142","author":"Durrough","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2022.101617_bb0035","series-title":"Boston, MA: Alexion Pharmaceuticals, Inc","year":"2020"},{"key":"10.1016\/j.bonr.2022.101617_bb0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2022.101617_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115664","article-title":"Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia","volume":"142","author":"Seefried","year":"2021","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bonr.2022.101617_bb0050","article-title":"Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia","volume":"4","author":"Genest","year":"2020","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bonr.2022.101617_bb0055","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.4130","article-title":"Burden of illness in adults with hypophosphatasia: data from the global hypophosphatasia patient registry","volume":"35","author":"Seefried","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2022.101617_bb0060","article-title":"Multigenerational case examples of hypophosphatasia: challenges in genetic counseling and disease management","volume":"25","author":"Huggins","year":"2020","journal-title":"Mol Genet Metab Rep."},{"issue":"8","key":"10.1016\/j.bonr.2022.101617_bb0065","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1210\/jc.2018-02413","article-title":"Letter to the editor: efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Rockman-Greenberg","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bonr.2022.101617_bb0070","first-page":"e344","article-title":"Adult-onset hypophosphatasia: before and after treatment with asfotase alfa","volume":"5","author":"Magdaleno","year":"2019","journal-title":"AACE Clin Case Rep."},{"issue":"5","key":"10.1016\/j.bonr.2022.101617_bb0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jbm4.10052","article-title":"Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy","volume":"2","author":"Klidaras","year":"2018","journal-title":"JBMR Plus."},{"issue":"9","key":"10.1016\/j.bonr.2022.101617_bb0080","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00198-018-4613-7","article-title":"Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia","volume":"29","author":"Bowden","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 1","key":"10.1016\/j.bonr.2022.101617_bb0085","first-page":"S300","article-title":"Deterioration of physical function and bone mineral density after discontinuation of asfotase alfa therapy in a young woman with infantile hypophosphatasia [abstract MO0394]","volume":"32","author":"Mohseni","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bonr.2022.101617_bb0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235218722200451X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235218722200451X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:25:07Z","timestamp":1762446307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235218722200451X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":18,"alternative-id":["S235218722200451X"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101617","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of discontinuing 5\u00a0years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2022.101617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101617"}}